Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Comarum palustre is a perennial herbaceous plant in the Rosaceae family commonly known as marsh cinquefoil. It is native to wetland areas across northern Europe, Asia, and North America. Traditionally used in folk medicine—especially in Siberia and by Native American tribes—the root has been employed for its astringent properties to treat dysentery and stomach cramps. Modern herbal use includes support for digestive health and immune function[1][5][6]. Recent studies suggest pleiotropic effects including reduction of pain and symptoms in osteoarthritis (OA), improvement of lipid profiles (decreased total cholesterol/increased HDL-C), anti-inflammatory activity (reduced TNF-α/increased IL-10), antioxidant effects due to ellagitannins like agrimoniin[2][4], and potential α-glucosidase inhibition relevant for diabetes management[4]. The main active constituents are ellagitannins such as agrimoniin; pectic polysaccharides like comaruman also contribute anti-inflammatory activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on comarum palustre.